Price Alert

Cohen & Steers Inc. (CNS)

NYSE: CNS · Real-Time Price · USD

66.58

-0.46 (-0.69%)

At close: Oct 15, 2025, 3:59 PM

66.55

-0.05%

After-hours: Oct 15, 2025, 04:17 PM EDT

-0.69% (1D)

Bid	66.44
Market Cap	3.4B
Revenue (ttm)	560.26M
Net Income (ttm)	162.12M
EPS (ttm)	3.15
PE Ratio (ttm)	21.14
Forward PE	19.61
Analyst	Hold
Dividends	$3.04

Ask	66.98
Volume	213,164
Avg. Volume (20D)	262,691.2
Open	67.39
Previous Close	67.04
Day's Range	66.06 - 67.59
52-Week Range	64.29 - 110.67
Beta	1.35
Ex-Dividend Date	Aug 11, 2025

About CNS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CNS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CNS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Cohen & Steers Inc. is scheduled to release its earnings on Oct 16, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 months ago

+9.62%

Shares of capital market companies are trading hig... Unlock content with Pro Subscription

6 months ago

+2.6%

Shares of financial stocks are trading higher amid overall market strength on reports of potentially narrowed or targeted tariffs, which may be easing investor concerns.

News

2 days ago · seekingalpha.com

Best High Yield Income Funds From Cohen & Steers

Cohen & Steers, Inc. offers high yield income funds paying monthly income yielding over 8%. Fund sectors include real estate, preferred securities, infrastructure, utilities, and fixed income. CNS's e...

6 days ago · businesswire.com

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...

1 week ago · zacks.com

AB vs. CNS: Which Stock Is the Better Value Option?

Investors looking for stocks in the Financial - Investment Management sector might want to consider either AllianceBernstein (AB) or Cohen & Steers Inc (CNS). But which of these two companies is the b...

1 week ago · accessnewswire.com

ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigatio...

3 weeks ago · seekingalpha.com

MapLight Therapeutics Starts $100 Million IPO Effort For CNS Treatments

MapLight Therapeutics is a clinical-stage biopharma focused on CNS disorders and has filed for a $100 million U.S. IPO to fund its pipeline. MPLT's lead drug, ML-07C-MA, targets schizophrenia and Alzh...

4 weeks ago · zacks.com

FHI vs. CNS: Which Stock Is the Better Value Option?

Investors looking for stocks in the Financial - Investment Management sector might want to consider either Federated Hermes (FHI) or Cohen & Steers Inc (CNS). But which of these two stocks presents in...

4 weeks ago · youtube.com

Cohen & Steers' Rosenlicht: Energy & natural resource valuations are low relative to rest of market

Tyler Rosenlicht, Cohen & Steers head of natural resource equities, joins CNBC's 'Power Lunch' to discuss his energy playbook.

1 month ago · accessnewswire.com

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo...

1 month ago · zacks.com

FHI or CNS: Which Is the Better Value Stock Right Now?

2 months ago · accessnewswire.com

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Strong cash position of $12.1 million expected to fund operations into the second half of 2026 Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUST...

Load More News